Enovix reaffirms Q3 revenue outlook of $9 million-$10 million

ENVX•2026-08-18

Q3 2026 guidance reaffirmed

Enovix reaffirmed Q3 2026 guidance despite a CEO transition, keeping its outlook unchanged.

Revenue is forecast at $9 million-$10 million, implying 13%-25% year-on-year growth.

Non-GAAP operating loss is expected at $29 million-$32 million; non-GAAP net loss per share is seen at $0.13-$0.17.

Capital expenditures are projected at $8 million-$12 million; cash, cash equivalents and marketable securities totaled about $552.1 million at the end of Q2 2026.

Sources

Enovix reaffirms Q3 revenue outlook of $9 million-$10 million

Publicnow

Enovix reaffirms Q3 revenue outlook of $9 million-$10 million

Q3 2026 guidance reaffirmed

Related News

Ingevity CEO David H. Li sells USD 765,877.32 in common shares

American Vanguard director Steven D. Macicek acquires 19,000 shares worth $39,710

Juniper Investment Company reports Orthofix Medical share disposal worth $402,483.1

Sources

Enovix reaffirms Q3 revenue outlook of $9 million-$10 million

Cid Holdco Receives Notice Of Default And Demand To Assemble Collateral From LHT I

ReposiTrak CFO Merrill signs employment deal with annual base salary of $325,000